Advances in targeting cyclic nucleotide phosphodiesterases
By D. Maurice, H. Ke, F. Ahmad, Yousheng Wang, Jay H. Chung, V. Manganiello. Nature reviews. Drug discovery, 2014
742 citations recorded by the source corpus.
Cyclic nucleotide phosphodiesterases (PDEs) catalyse the hydrolysis of cyclic AMP and cyclic GMP, thereby regulating the intracellular concentrations of these cyclic nucleotides, their signalling pathways and, consequently, myriad biological responses in health and disease. Currently, a small number of PDE inhibitors are used clinically for treating the pathophysiological dysregulation of cyclic nucleotide signalling in several disorders, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, intermittent claudication and chronic obstructive pulmonary disease. However, pharmaceutical interest in PDEs has been reignited by the increasing understanding of the roles of individual PDEs in regulating the subcellular compartmentalization of specific cyclic nucleotide signalling pathways, by the structure-based design of novel specific inhibitors and by the development of more sophisticated strategies to target individual PDE variants.
Subfields: Molecular Biology, Oncology, Organic Chemistry
View Paper: https://www.semanticscholar.org/paper/78d957e60a95655eebdf9c1250a35abadcef6b04
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Oncology
Citations in the corpus
- Regulation of tumour necrosis factor signalling: live or let die (2015, background): “Roflumilast shows efficacy in patients with chronic obstructive pulmonary disease and apremilast reduces inflammation in patients with psoriasis or psoriatic arthritis 164,165 .”